Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
about
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.Level of evidence for therapeutic drug monitoring of taxanes.Loss of SLCO1B3 drives taxane resistance in prostate cancerNo Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies.Influence of drug formulation on OATP1B-mediated transport of paclitaxel.Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.Docetaxel-loaded thermosensitive liquid suppository: optimization of rheological properties.Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect.Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors.Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.Lessons learned from development of docetaxel
P2860
Q33315395-107EBD23-38C1-4511-A54B-16C59416543BQ35523387-815BD252-FF35-43CF-BC12-06BF9DF56564Q36072512-E3EC8090-9FA6-49F8-8946-47E8AED7ADFAQ36296752-5161417B-1AC7-4043-ADCB-22FB907B3779Q36326889-0193465D-1C79-4C46-BA13-825BA782E6AEQ36940993-39E5E15A-4A6C-4460-B8FE-64874F18C4D5Q37788732-679D5F18-6BBE-4695-BB02-16CA3DA20B02Q38751260-34992413-6162-4905-BD57-4CFA5C8BD018Q38894543-4E35CDC4-90AD-46CF-949D-992A517A1E03Q39001980-12D9DD74-79C1-4FC0-ACA4-5A9528846644Q39317847-AD6D6781-9D3C-483B-BAD4-642AE94F977FQ44026300-B058BB7C-10A5-425C-BEB2-08AB669695F5Q46396503-826157BA-6CD7-4EE3-B3FA-C32EF7EFAF30Q47943718-7620C23F-D277-4076-962A-FBA461B36D8EQ53792451-C736D859-D831-4254-8693-0C1D93228FCAQ58382477-0D3E2DCD-C358-40B0-A861-F6B2756DA25E
P2860
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@ast
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@en
type
label
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@ast
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@en
prefLabel
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@ast
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@en
P2093
P356
P1476
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
@en
P2093
Frederike K Engels
Jaap Verweij
Ron A A Mathot
Ron H N van Schaik
Walter J Loos
P304
P356
10.4161/CBT.5.7.2839
P577
2006-07-22T00:00:00Z